A new genetic testing platform is set to launch at the Institut de Cancérologie de l’Ouest (ICO) in Angers, France, in September 2026, with services extending to the Saint-Herblain site. This initiative, supported by funds raised through the Odysséa Nantes event, promises to significantly improve cancer care through a more comprehensive understanding of a patient’s genetic makeup.
The platform will focus on analyzing both acquired tumor anomalies and constitutional genetics – the genetic information a person is born with – to identify potential hereditary predispositions to cancer. This holistic approach aims to refine treatment strategies and provide more personalized care for patients and their families.
Understanding a Patient’s Genetic Heritage
According to the ICO, the new platform will allow clinicians to “explore the patient’s genetic heritage ‘from birth,’ present in all their cells, in order to identify any hereditary predispositions.” This analysis complements existing tumor genetic testing, providing a more complete picture for both the patient and their family.
The platform will utilize advanced molecular biology techniques to analyze DNA and detect genetic anomalies present from conception, distinct from mutations acquired during a person’s lifetime. Identifying these inherited predispositions can help tailor therapeutic approaches and enable targeted treatments.
Family members of patients may also benefit from this testing through early screening and personalized preventative measures, including adjustments to follow-up exam schedules, such as mammograms and ultrasounds.
▶ A LIRE AUSSI : Odysséa revient bientôt à Nantes et rencontre toujours un succès impressionnant
Faster Analysis Times
The ICO plans to initially focus on breast, ovarian, prostate, and pancreatic cancers – representing approximately 60% of cases – before expanding to include digestive cancers, such as colorectal cancer. The implementation of this platform is expected to reduce analysis turnaround times from the current 6 to 12 months to around 3 months, eliminating the need for external outsourcing.
The development of this expertise required two years of work and received approval from relevant authorities in 2024. The platform will be equipped with state-of-the-art technology, including a high-throughput sequencer, a Sanger sequencer, and a robotic sample preparation system.
